SCHEMBL6640024

SCHEMBL6640024

NC(=O)C1CCC(CNC(=O)c2ccccc2)C1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC3 O15379 4/20 0.55
▸ HDAC4 P56524 3/20 0.55
▸ HDAC1 Q13547 3/20 0.55
▸ HDAC7 Q8WUI4 3/20 0.55
▸ HDAC2 Q92769 3/20 0.55
▸ HDAC10 Q969S8 3/20 0.55
▸ HDAC11 Q96DB2 3/20 0.55
▸ HDAC8 Q9BY41 3/20 0.55
▸ HDAC6 Q9UBN7 3/20 0.55
▸ HDAC9 Q9UKV0 3/20 0.55
▸ HDAC5 Q9UQL6 3/20 0.55
▸ CTSL P07711 1/20 0.53
▸ CTSB P07858 1/20 0.53
▸ CTSK P43235 1/20 0.53
▸ SMN1; SMN2 Q16637 2/20 0.53
▸ MAPK14 Q16539 2/20 0.48
▸ HPGD P15428 1/20 0.48
▸ KDM4E B2RXH2 1/20 0.46
▸ PKM P14618 1/20 0.46
▸ IDO1 P14902 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6641152 0.92 HDAC1 (0.67) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL6637776 0.92 SMN1; SMN2 (0.52) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL6636821 0.86 CACNA1H (0.48) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL2303341 0.83 HDAC3 (0.64) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL6643580 0.82 CTSL (0.56) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL6641299 0.82 CTSL (0.56) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL6640027 0.82 CTSL (0.56) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL8598520 0.82 HDAC3 (0.64) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL7487285 0.82 HDAC3 (0.64) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL14504650 0.81 CTSL (0.55) HDAC3HDAC4HDAC1HDAC7HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1250340-B1 METHODS AND COMPOUNDS FOR INHIBITING MRP1 LILLY CO ELI (US) 2004-11-17 — — EP disclosed
US-20040176405-A1 Methods and compounds for inhibitting MRP1 KROIN JULIAN (US) 2004-09-09 — — US disclosed
EP-1250340-A1 METHODS AND COMPOUNDS FOR INHIBITING MRP1 ELI LILLY AND COMPANY (US) 2002-10-23 — — EP disclosed
WO-2001046199-A1 METHODS AND COMPOUNDS FOR INHIBITING MRP1 ELI LILLY AND COMPANY (US) 2001-06-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040176405-A1 Methods and compounds for inhibitting MRP1 ABCC1, ABCB11, ABCB1 HDAC3 2180/4885HDAC4 3940/4885HDAC1 1919/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback